Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. METHODS: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. RESULTS: If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0-30%), between 2016-2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15-56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. CONCLUSIONS: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. LAY SUMMARY: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Self-citationVernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Research works printed but not linked: 6
- Kern B, Newsome P, Karam V, Adam R, Berlakovich G, Fritz J, et al. Nonalcoholic steatohepatitis as indication for liver transplantation in Europe. Do we choose the right organs for the right recipients? American Transplant Conference; 2015 May 4, 2015; Philadelphia, Pennsylvania; 2015.
- Marmur, 2010, Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome, Scand J Gastroenterol, 45, 60, 10.3109/00365520903384742 · DOI
- Huang, 2013, The national program for deceased organ donation in China, Transplantation, 96, 5, 10.1097/TP.0b013e3182985491 · doi:10.1097/tp.0b013e3182985491
- Delmonico, 2013, A welcomed new national policy in China, Transplantation, 96, 3, 10.1097/TP.0b013e31829949fb · doi:10.1097/tp.0b013e31829949fb
- Wang, 2013, Responses to comments on “Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report”, Hepatobiliary Surg Nutr, 2, 309
- Aberg, 2011, Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score, Liver Transpl, 17, 1333, 10.1002/lt.22388 · doi:10.1002/lt.22388
Cited by
Items 101–112 of 112
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
A decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30
Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis
Wang, G., Huang, Y., Yang, H., Lin, H., Zhou, S., & Qian, J. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.12.025 · Cited by 29
Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104949 · Cited by 28
Self-citationModeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Self-citationHuang, L., Zeng, X., Li, B., Wang, C., Zhou, M., Lang, H., Yi, L., & Mi, M. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00612-w · Cited by 23
When Metabolic Dysfunction-Associated Steatotic Liver Disease Meets Viral Hepatitis
Hasanoglu, I., Rivero-Juárez, A., Özkaya Şahin, G., & ESCMID Study Group for Viral Hepatitis (ESGVH) (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103422 · Cited by 22
“Meanwhile, in Western countries, metabolic factors are the primary drivers of liver disease, complicating HCV eradication efforts amid rising MASLD prevalence [10].”
MMP10 alleviates non-alcoholic steatohepatitis by regulating macrophage M2 polarization
Chang, L., Gao, J., Yu, Y., Liao, B., Zhou, Y., Zhang, J., Ma, X., Hou, W., Zhou, T., & Xu, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111045 · Cited by 20
Saki, N., Hashemi, S. J., Hosseini, S. A., Rahimi, Z., Rahim, F., & Cheraghian, B. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01255-5 · Cited by 20
Collagen-targeted molecular imaging in diffuse liver diseases
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C., & Caravan, P. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02677-2 · Cited by 14
Yang, L., Zhang, Y., Hong, X., Zhang, K., Liu, B., Zhang, P., Tang, Q., Yu, J., Jin, X.-Z., Jin, X.-Z., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03502-z · Cited by 7
Shea, S., Lionis, C., Kite, C., Atkinson, L., Chaggar, S. S., Randeva, H. S., & Kyrou, I. (2021) · Biomedicines · doi:10.3390/biomedicines9111697 · Cited by 4
Metadata
- Authors
- Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., Eguchi, Y., Geier, A., Kondili, L. A., Kroy, D. C., Lazarus, J. V., Loomba, R., Manns, M. P., Marchesini, G., Nakajima, A., Negro, F., Petta, S., Ratziu, V., Romero-Gomez, M., Sanyal, A., Schattenberg, J. M., Tacke, F., Tanaka, J., Trautwein, C., Wei, L., Zeuzem, S., & Razavi, H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 69
- Issue
- 4
- Pages
- 896-904
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2806839461
- Cited by
- 1,980
- References
- 60
- FWCI
- 94.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.